NEW YORK and MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ICBS Limited (PINKSHEETS: ICBM), today announced the acquisition of 30% interest in Bacteria Bank Ltd.
Bacteria Bank Ltd., is a Bio medical company that owns over ten thousand cryogenically stored bacteria for use in medical research, located in Montreal Canada. The company is headed by Dr. Karl Weiss a world renowned bacteriologist.
Dr. Karl Weiss is a Microbiologist and Infectious Diseases Specialist at Maisonneuve-Rosemont Hospital in Montreal . He is also Associate Clinical Professor at the Faculty of Medicine at University of Montreal , and the director of pharmacological research at Maisonneuve-Rosemont hospital. He is also an associate member of the division of infectious diseases at the Jewish General Hospital in Montreal , and an adjunct-professor of Medicine at McGill University.
Bacteria bank has a unique collection of over 10,000 frozen bacteria which can be used for many different purposes.
1. susceptibility testing of potentially promising anti-microbial
agents developed by biotech companies or researchers in
2. susceptibility testing of new antibiotics against specific and
emerging pathogens such as MRSA ( Methicillin resistant
Staphyloccocus aureus), VRE ( Vancomycin Resistant Enterococcus).
3. susceptibility testing against a wide array of Gram negative
agents ( E. coli, Salmonella, shigella, and other gastro-
intestinal pathogens responsible for million of deaths every year
in the world)
4. susceptibility testing of new agents against Streptococcus
pneumoniae responsible for the majority of sinusitis, otitis
media, pneumonia and some forms of bronchitis. In North America
only, there are over 300 million of antibiotic prescriptions in
the outpatients setting, and S.pneumonie is the number one target
overall by far.
5. bacteria useful for the development of newly designed genetically
derived products ( human and animal hormones, growth factors,
6. bacteria useful for teaching purposes ( Pharmaceutical companies,
universities and medical schools)
Speaking from the corporate head office in Montreal, Garth McIntosh, President &CEO of ICBS said, " This acquisition will further strengthen our position in the Bio medical industry". ICBS also owns 100% of Canadian Bio Med Systems Ltd. McIntosh further stated " I want to thank all of our shareholders that have supported us in the past year, we are working very hard to make this a profitable year for all. Thank you all for your encouragement and support".
You can visit them at: http://www.bacteriabank.com
This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.
|SOURCE INTER CANADIAN BUSINESS SERVICE|
Copyright©2007 PR Newswire.
All rights reserved